Abstract
A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Clinical Cancer Drugs
Title:Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art
Volume: 1
Author(s): Lisa Salvatore, Fotios Loupakis, Andrea Ciarlo, Chiara Cremolini, Camilla Comin, Marta Schirripa, Luca Messerini, Federica Marmorino, Carlotta Antoniotti and Alfredo Falcone
Affiliation:
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Abstract: A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Export Options
About this article
Cite this article as:
Salvatore Lisa, Loupakis Fotios, Ciarlo Andrea, Cremolini Chiara, Comin Camilla, Schirripa Marta, Messerini Luca, Marmorino Federica, Antoniotti Carlotta and Falcone Alfredo, Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X0101131204152941
DOI https://dx.doi.org/10.2174/2212697X0101131204152941 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses
Current Cancer Drug Targets Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Dual Roles of Pin1 in Cancer Development and Progression
Current Pharmaceutical Design Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?
Anti-Cancer Agents in Medicinal Chemistry From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry Selenium and Colon Cancer – From Chemoprevention to New Treatment Modality
Anti-Cancer Agents in Medicinal Chemistry Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Past, Present and Future of Targeted Therapy in Solid Tumors
Current Cancer Drug Targets Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Complex Network and Gene Ontology in Pharmacology Approaches:Mapping Natural Compounds on Potential Drug Target Colon Cancer Network
Current Bioinformatics